Blue Cross Blue Shield
US$ 21.32
amgen glp 1 drug Amgen's AMG-133 shows potential in competing with GLP-1RA obesity therapies Will 2 incretin drugs be
Description
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy
GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health
Lancet Gastroenterol Hepatol 5(11):10171026
The cost of GLP-1 receptor agonists is about two to three times higher than SGLT-2 inhibitors
